Business Wire04.25.18
Samsung NeuroLogica, a subsidiary of Samsung Electronics Co. Ltd., announced that the Samsung RS85A ultrasound system has received U.S. Food and Drug Administration 510(k) clearance. The RS85A is the latest expansion of Samsung’s ultrasound portfolio.
“We are pleased to launch the RS85A, a new premium general imaging ultrasound system with superior image quality and usability based on Samsung’s advanced ultrasound and radiology technologies,” said Philip Sullivan, president and CEO of Samsung NeuroLogica. “The RS85A embodies Samsung’s commitment to providing leading technologies to healthcare providers by combining our key values of access, accuracy and efficiency.”
The release of the RS85A is the latest demonstration of Samsung’s leadership in ultrasound. It features an array of improvements, including:
The RS85A was also developed to help decrease user-fatigue and repetitive motions with an enhanced monitor arm and increased range of motion and tilt. These improvements allow the user to position the monitor for optimal viewing and control. Additionally, multi-step actions have been combined into a single step to help reduce keystrokes and repetitive user interface interactions.
“Samsung has built diagnostic ultrasound products for more than 30 years,” said David Legg, vice president of sales at Samsung NeuroLogica. “We are so confident that our RS85A ultrasound system will perform reliably and be the system that you can depend on for years to come, that we are proud to offer a five-year warranty standard, at no additional cost.”
Samsung NeuroLogica, the healthcare subsidiary of Samsung Electronics Co. Ltd., develops, manufactures, and markets imaging technologies. Samsung NeuroLogica, the global corporate headquarters and manufacturer of Samsung computed tomography, is also the U.S. headquarters for sales, marketing, and distribution of all Samsung digital radiography and ultrasound systems. Samsung NeuroLogica’s growing portfolio of advanced medical technologies are used worldwide, helping providers enhance patient care, improve patient satisfaction and increase workflow efficiency.
“We are pleased to launch the RS85A, a new premium general imaging ultrasound system with superior image quality and usability based on Samsung’s advanced ultrasound and radiology technologies,” said Philip Sullivan, president and CEO of Samsung NeuroLogica. “The RS85A embodies Samsung’s commitment to providing leading technologies to healthcare providers by combining our key values of access, accuracy and efficiency.”
The release of the RS85A is the latest demonstration of Samsung’s leadership in ultrasound. It features an array of improvements, including:
- MV-Flow: Allows for visualization of slow-flow micro vascularized structures, which can be difficult to assess with conventional power Doppler ultrasound. It also provides clinicians an additional way to check lesions for indications of cancer or inflammation.
- S-Shearwave Imaging: Provides new indicators for clinical diagnosis by quantifying the elasticity of tissue or lesions via shearwave elastography, which may help increase the accuracy of diagnosis for breast and liver diseases.
- CEUS+: Diagnoses and characterizes lesions in the liver using a contrast agent in adult and pediatric populations.
- S-Fusion: Enables simultaneous localization of a lesion using real-time ultrasound in conjunction with other volumetric imaging modalities such as an MRI or a CT, while expanding its capabilities to the prostate gland for precise, targeted biopsy guidance.
The RS85A was also developed to help decrease user-fatigue and repetitive motions with an enhanced monitor arm and increased range of motion and tilt. These improvements allow the user to position the monitor for optimal viewing and control. Additionally, multi-step actions have been combined into a single step to help reduce keystrokes and repetitive user interface interactions.
“Samsung has built diagnostic ultrasound products for more than 30 years,” said David Legg, vice president of sales at Samsung NeuroLogica. “We are so confident that our RS85A ultrasound system will perform reliably and be the system that you can depend on for years to come, that we are proud to offer a five-year warranty standard, at no additional cost.”
Samsung NeuroLogica, the healthcare subsidiary of Samsung Electronics Co. Ltd., develops, manufactures, and markets imaging technologies. Samsung NeuroLogica, the global corporate headquarters and manufacturer of Samsung computed tomography, is also the U.S. headquarters for sales, marketing, and distribution of all Samsung digital radiography and ultrasound systems. Samsung NeuroLogica’s growing portfolio of advanced medical technologies are used worldwide, helping providers enhance patient care, improve patient satisfaction and increase workflow efficiency.